The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
Open accessAbstract
Introduction: We used the data of the German biologics register RABBIT, a nationwide prospective cohort study, to investigate the risk of new or recurrent malignancy in patients with rheumatoid arthritis (RA) receiving biologics compared to conventional disease modifying anti-rheumatic drugs (DMARDs). Methods: The analysis was based on patients with RA enrolled in RABBIT at the start of a biologic or conventional DMARD therapy between 01 May 2001 and 31 December 2006. Incidences of first or recurrent malignancies were analysed separately. A nested case-control design was used to investigate the risk of developing a first malignancy. Matching criteria were: age, gender, follow-up time, disease activity score based on 28 joint counts (DAS28) at study entry, smoking status, and selected chronic co-morbid conditions (obstructive or other lung disease, kidney, liver or gastrointestinal disease, psoriasis). Results: A prior malignancy was reported in 122 out of 5,120 patients. Fifty-eight of these patients had received anti-TNFα agents, 9 anakinra, and 55 conventional DMARDs at study entry. In 14 patients (ever exposed to anti-TNFα: eight, to anakinra: one) 15 recurrent cancers were observed. The average time period since the onset of the first malignancy was nine years. Crude recurrence rates per 1,000 patient-years (pyrs) were 45.5 for patients exposed to anti-TNFα agents, 32.3 for anakinra patients and 31.4 for patients exposed to DMARDs only (Incidence rate ratio anti-TNFα vs. DMARD = 1.4, P = 0.6.). In patients without prior cancer, 74 patients (70% female, mean age: 61.3) developed a first malignancy during the observation. This corresponds to an incidence rate (IR) of 6.0/1,000 pyrs. Forty-four of these patients were ever exposed to anti-TNFα treatment (IR = 5.1/1,000 pyrs). In a nested case-control study comparing cancer patients to cancer-free controls, 44 of the cancer patients and 44 of the cancer-free controls were ever exposed to anti-TNFα agents (P = 1.0). Conclusions: No significant differences in the overall incidence of malignancies in patients exposed or unexposed to anti-TNFα or anakinra treatment were found. The same applied to the risk of recurrent malignancies. However, in particular this last finding needs further validation in larger data sets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maximum Likelihood from Incomplete Data Via the EM Algorithm
Dempster, A. P., Laird, N. M., & Rubin, D. B. (1977) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1977.tb01600.x · Cited by 50,444
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
TNF-α in promotion and progression of cancer
Balkwill, F. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9005-3 · Cited by 915
Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21675 · Cited by 890
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
Strangfeld, A. (2009) · JAMA · doi:10.1001/jama.2009.146 · Cited by 542
Self-citationWolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 534
Collett, D. (1994) · Modelling Survival Data in Medical Research · doi:10.1007/978-1-4899-3115-3_3 · Cited by 518
TNF: A master switch for inflammation to cancer
Sethi, G. (2008) · Frontiers in Bioscience · doi:10.2741/3066 · Cited by 458
Baecklund, E., Ekbom, A., Sparén, P., Feltelius, N., & Klareskog, L. (1998) · BMJ · doi:10.1136/bmj.317.7152.180 · Cited by 394
Askling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033993 · Cited by 377
NF-κB: tumor promoter or suppressor?
Perkins, N. D. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2003.12.004 · Cited by 261
Zink, A., Strangfeld, A., Schneider, M., Herzer, P., Hierse, F., Stoyanova‐Scholz, M., Wassenberg, S., Kapelle, A., & Listing, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22193 · Cited by 239
Self-citationMadhusudan, S., Foster, M., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F., Talbot, D. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0730 · Cited by 205
Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer
Madhusudan, S., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F., & Ganesan, T. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.127 · Cited by 167
Cancer morbidity in rheumatoid arthritis.
Prior, P., Symmons, D. P., Hawkins, C. F., Scott, D. L., & Brown, R. (1984) · Annals of the Rheumatic Diseases · doi:10.1136/ard.43.2.128 · Cited by 162
Bongartz, T., Warren, F. C., Mines, D. I., Matteson, E. L., Abrams, K. R., & Sutton, A. J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094904 · Cited by 155
Treatment continuation in patients receiving biological agents or conventional DMARD therapy
Zink, A., Listing, J., Kary, S., Ramlau, P., Stoyanova-Scholz, M., Babinsky, K., von Hinueber, U., Gromnica-Ihle, E., Wassenberg, S., Antoni, C., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031476 · Cited by 152
Self-citationLautenschläger, J., Mau, W., Kohlmann, T., Raspe, H. H., Struve, F., Brückle, W., & Zeidler, H. K. (1997) · Zeitschrift für Rheumatologie · doi:10.1007/s003930050030 · Cited by 148
Dixon, W. G., & Silman, A. J. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2026 · Cited by 52
Cited by
Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30173-8 · Cited by 4,870
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
Self-citationSmolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.1 · Cited by 2,445
Self-citationNovel treatment strategies in rheumatoid arthritis
Burmester, G. R., & Pope, J. E. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31491-5 · Cited by 1,068
Self-citation
Metadata
- Authors
- Strangfeld, A., Hierse, F., Rau, R., Burmester, G.-R., Krummel-Lorenz, B., Demary, W., Listing, J., & Zink, A.
- Venue
- Arthritis Research & Therapy
- Published
- 2010-01-08
- Volume
- 12
- Issue
- 1
- Pages
- R5-R5
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2062694326
- Cited by
- 264
- References
- 21
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.